G protein subunit alpha 15Genealiases: GNA16 · HG1L
Q-omics provides the consensus-scored GNA15 profile across patient tissues and cancer cell-line models. GNA15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GNA15 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GNA15 RNA expression shows 19,383 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KIRC, and GBM as cancer lineages where GNA15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNA15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNA15 survival associations across molecular data types. GNA15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNA15 RNA expression–survival associations across cancer types. High GNA15 expression shows unfavorable associations in PAAD, THCA, OV and LUSC, but favorable associations in UCEC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GNA15 RNA expression.
This table summarizes GNA15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GNA15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNA15 shows higher tumor expression in KIRC, THCA, COAD, KIRP, LUSC and LUAD. The KIRC box plot shows higher GNA15 RNA expression in tumor versus normal tissue (log2 FC = +1.658, t-test p < 0.001).
This table shows molecular features associated with GNA15 in patient tissues and cancer cell lines. In patient samples, GNA15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNA15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
